Long-term follow-up shows epcoritamab drives deep, durable responses in relapsed/refractory follicular lymphoma (R/R FL)

被引：0
|
作者：
Izutsu, K. [1 ]
Akahane, D. [2 ]
Toubai, T. [3 ]
Saito, T. [4 ]
Mishima, Y. [5 ]
Fujisaki, T. [6 ]
Kitawaki, T. [7 ]
Kumode, T. [8 ]
Suehiro, Y. [9 ]
Ishitsuka, K. [10 ]
Conlon, R. [11 ]
Noguchi, H. [12 ]
Buchbjerg, J. [13 ]
Favaro, E. [13 ]
Fukuhara, N. [14 ]
机构：
[1] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[2] Tokyo Med Univ, Dept Hematol, Tokyo, Japan
[3] Yamagata Univ, Div Hematol & Cell Therapy, Fac Med, Yamagata, Japan
[4] Aichi Canc Ctr Hosp, Dept Hematol & Cell Therapy, Nagoya, Aichi, Japan
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol Oncol, Tokyo, Japan
[6] Matsuyama Red Cross Hosp, Japan Red Cross Soc, Dept Hematol, Matsuyama, Ehime, Japan
[7] Kyoto Univ Hosp, Dept Hematol & Oncol, Kyoto, Japan
[8] Kindai Univ, Dept Hematol & Rheumatol, Osaka, Japan
[9] Natl Hosp Org Kyushu Canc Ctr, Dept Hematol & Cell Therapy, Fukuoka, Japan
[10] Kagoshima Univ Hosp, Dept Hematol & Rheumatol, Kagoshima, Japan
[11] AbbVie, N Chicago, IL USA
[12] Genmab KK, Tokyo, Japan
[13] Genmab AS, Copenhagen, Denmark
[14] Tohoku Univ, Dept Hematol, Sendai, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.548
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO20-2
引用
收藏
页码：S1337 / S1337
页数：1
相关论文
共 50 条
  • [31] EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma
    Falchi, Lorenzo
    Morschhauser, Franck
    Linton, Kim
    Huang, Huiqiang
    Galderisi, Faith
    Quadri, Syed
    Zeng, Lingmin
    Hoehn, Daniela
    Seymour, John F.
    BLOOD, 2023, 142
  • [32] Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma
    Puckrin, Robert
    Chua, Neil
    Chin, Kelly
    Peters, Anthea
    Duggan, Peter
    Shafey, Mona
    Storek, Jan
    Jamani, Kareem
    Owen, Carolyn
    Stewart, Douglas
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (02) : 319 - 325
  • [33] Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells
    Awasthi, Rakesh
    Waldron, Edward
    Grupp, Stephan
    Pulsipher, Michael A.
    Bader, Peter
    Schuster, Stephen J.
    Maziarz, Richard T.
    Waller, Edmund K.
    Jaeger, Ulrich
    Thieblemont, Catherine
    Dreyling, Martin
    Fowler, Nathan
    Maier, Harald Jakob
    Willert, Jennifer
    BLOOD, 2023, 142
  • [34] ECONOMIC EVALUATIONS IN RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): CHALLENGES FOR HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS
    Forbes, C.
    Pustulka, I
    Zuchinali, P.
    Kumar, J.
    VALUE IN HEALTH, 2023, 26 (12) : S334 - S334
  • [35] Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma
    Strati, Paolo
    Jain, Preetesh
    Johnson, Ralph J.
    Forbes, Sheryl
    Feng, Lei
    Samaniego, Felipe
    Rodriguez, Maria A.
    Fayad, Luis E.
    Hagemeister, Fredrick
    Westin, Jason
    Wang, Michael
    Neelapu, Sattva S.
    Nastoupil, Loretta J.
    Fowler, Nathan H.
    BLOOD, 2021, 137 (08) : 1124 - 1129
  • [36] Stage III follicular lymphoma: Long-term follow-up and patterns of failure
    Ha, CS
    Kong, JS
    McLaughlin, P
    Tucker, SL
    Fayad, LE
    Hess, MA
    Wilder, RB
    Cabanillas, F
    Cox, JD
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (03): : 748 - 754
  • [37] Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up
    Song, Yuqin
    Zhou, Keshu
    Li, Dengju
    Hu, Jianda
    Zou, Dehui
    Gao, Sujun
    Yang, Haiyan
    Zhang, Huilai
    Ji, Jie
    Xu, Wei
    Feng, Ru
    Jin, Jie
    Lyu, Fangfang
    Fang, Cheng
    Xu, Sheng
    Zhu, Jun
    BLOOD, 2023, 142
  • [38] Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.
    Song, Yuqin
    Gao, Quanli
    Zhang, Huilai
    Fan, Lei
    Zhou, Jianfeng
    Zou, Dehui
    Li, Wei
    Yang, Haiyan
    Liu, Ting
    Wang, Quanshun
    Lv, Fangfang
    Guo, Haiyi
    Yang, Liudi
    Huang, Jane
    Novotny, William F.
    Wang, Yidi
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term responses in patients with relapsed or refractory follicular lymphoma (FL).
    Schilder, RJ
    Witzig, TE
    Flinn, I
    Gordon, LI
    Emmanouilides, C
    Wang, H
    Vo, K
    Molina, A
    BLOOD, 2004, 104 (11) : 719A - 719A
  • [40] Rituximab maintenance therapy (RM) for relapsed/refractory follicular lymphoma (FL): Long-term economic impact in the French setting
    Brice, P.
    Miadi-Fargier, H.
    Le Pen, C.
    Pacull, A.
    Coudray-Omnes, C.
    Deconinck, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345